---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-032333"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-07-03T23:59:59+00:00"
generated_at: "2026-05-31T23:26:43.165309+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Insmed reports additional positive ASPEN data: brensocatib 25 mg slows lung function decline in bronchiectasis

## Summary
- Brensocatib 25 mg showed significantly less FEV1 decline vs placebo (38 mL vs -62 mL; p=0.0054) at Week 52.
- Brensocatib 25 mg also showed nominally significant FVC preservation (75 mL less decline; p<0.0001).
- QOL-B Respiratory Symptom Score improved by 3.8 points with 25 mg dose vs placebo (p=0.0004).
- Safety profile favorable; common TEAEs included COVID-19, nasopharyngitis, cough, headache.
- Insmed plans to file NDA in Q4 2024; potential U.S. launch mid-2025, Europe/Japan H1 2026.

## SEC filing metadata
- accession: 0001140361-24-032333
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-07-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124032333/0001140361-24-032333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124032333/ef20031846_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-032333
- JSON: https://secwatch.observer/filing/0001140361-24-032333.json
- Plain text: https://secwatch.observer/filing/0001140361-24-032333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.